期刊
DIABETES OBESITY & METABOLISM
卷 17, 期 6, 页码 533-540出版社
WILEY
DOI: 10.1111/dom.12449
关键词
gender; hypoglycaemia; insulin glargine; NPH insulin; type 2 diabetes
资金
- Sanofi
Aims: To determine the impact of gender on glycaemic control and hypoglycaemia in insulin-naive patients with type 2 diabetes (T2DM). Methods: Data were pooled from six randomized clinical trials of insulin glargine or NPH insulin in insulin-naive, inadequately controlled patients. Female [n=1251; mean glycated haemoglobin (HbA1c) level 8.99%, age 56.91 years, diabetes duration 9.84 years] and male patients (n=1349; mean HbA1c 8.9%, age 57.47 years, diabetes duration 10.13 years) were started on and treated with insulin glargine or NPH insulin for 24-36 weeks. HbA1c and fasting blood glucose levels, percent achieving HbA1c target of <7% and insulin dose change were recorded. Results: For both men and women, HbA1c levels were significantly reduced over time (p<0.001); a significantly greater HbA1c reduction was observed inmen than in women (-1.36 vs. -1.22; p= 0.002). Significantly fewer women achieved target HbA1c of < 7% (p< 0.001). At the study end, women had a significantly higher insulin dose/kg than men (0.47 vs. 0.42 U/kg; p< 0.001). The incidence rates of severe and severe nocturnal hypoglycaemia were significantly higher in women (3.28% vs. 1.85%; p< 0.05 and 2.24% vs. 0.59%; p< 0.001, respectively). Women were more likely to experience severe hypoglycaemia [odds ratio (OR) 1.80; 95% confidence interval (CI) 1.08, 3.00; p= 0.02] and severe nocturnal hypoglycaemia (OR: 3.80; 95% CI 1.72, 8.42; p= 0.001). Conclusions: These observations confirm studies that found a smaller improvement in HbA1c and greater hypoglycaemia in women during insulin treatment. Physicians should be aware of the need to determine and closely monitor dosing, particularly in women, to optimize the balance between glycaemic control and hypoglycaemia risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据